Article Information
History
- February 19, 2021.
Article Versions
- You are currently viewing Version 1 of this article (February 19, 2021 - 09:38).
- View Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Emily J. Ciccone, MD, MHS1,
- Deanna R. Zhu, BA2,
- Rawan Ajeen, BSPH2,
- Bonnie E. Shook-Sa, DrPH3,
- Ross M. Boyce, MD, MSc1,
- Allison E. Aiello, PhD, MS2,*,
- the COVID HCP Study Team
- 1Division of Infectious Diseases, School of Medicine, University of North Carolina
- 2Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina
- 3Department of Biostatistics, Gillings School of Global Public Health, University of North Carolina
- ↵*Corresponding Author Information: Gillings School of Global Public Health, CB #7435, Chapel Hill, NC 27599, USA Email: aaiello{at}email.unc.edu
- 1Institute for Global Health and Infectious Diseases, University of North Carolina
- 2Department of Hospital Medicine, School of Medicine, University of North Carolina
- 3Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina
- 4Division of Infectious Diseases, School of Medicine, University of North Carolina
Posted February 19, 2021.
SARS-CoV-2 seropositivity after infection and antibody response to mRNA-based vaccination
